This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
fluoxetine
Fluoxetine
Selective serotonin reuptake inhibitor (SSRI); blocks SERT → ↑ synaptic 5-HT → downstream neuroplasticity via BDNF/TrkB. First-line for MDD, OCD, panic disorder, bulimia, PMDD. Long half-life (1–6 days + active metabolite). Prozac; ~40 million users.
Entry Metadata
| Field | Value |
|---|---|
| ID | fluoxetine |
| Name | Fluoxetine |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Stream | 01-modern |
Cross-Atlas Connections
Sources
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. Lancet. 2018;391(10128):1357-1366. · PubMed 29477251
- Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32 Suppl 1:1-21. · PubMed 9068931
- Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol. 2010;70(5):289-97. · PubMed 20186710
- Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-9. · PubMed 16520440